Different glucose metabolism behavior relating to histotypes in synchronous breast cancers evaluated by [18F]FDG PET-CT

Abstract

Glucose metabolism is increased in most aggressive tumors and it is commonly evaluated by positron emission tomography-computed tomography (PET-CT) with 18 F-fluorodeoxyglucose ([ 18 F]FDG), measuring the Maximum Standardized Uptake Value (SUVmax) for the assessment. Particularly, it is known that breast cancer expresses different glucose metabolism in relation to estrogen receptor (ER), progesterone receptor (PR), Ki67 score, tumor grading, tumor size, and Human Epidermal Growth Factor Receptor 2 (HER2). We present an interesting case of a woman with two different, synchronous breast cancers characterized by different glucose metabolism, according to literature knowledge.

Relationship between Baseline [18F]FDG PET/CT Semiquantitative Parameters and BRCA Mutational Status and Their Prognostic Role in Patients with Invasive Ductal Breast Carcinoma

“…The radiological diagnosis of BC is based on the use of various imaging techniques including mammography, ultrasound (US), computed tomography (CT), and nuclear magnetic resonance spectroscopy (MR) [ 12 ]. In the last decade, the role of positron emission tomography/CT (PET/CT) with various tracers and, in particular, fluorine-18 fluorodeoxyglucose ([ 18 F]FDG) for the assessment of a great number of neoplastic and non-neoplastic diseases is increasing, and the thoracic district does not make an exception [ 13 , 14 , 15 , 16 , 17 ]. In this setting, the role of this hybrid imaging modality for the staging and restaging of BC has been proven, given its ability to evaluate the whole body [ 18 ].…”